Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Medical Officer | January 06, 2023 | January 10, 2023 |
| Opus Genetics, Inc.RNN · Entity 5892 | Chief Medical Officer | February 28, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date January 06, 2023 · Filed January 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 28,770 |
Reported balance
After 2023-01-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-06 · Grant · Acquired 98 · Balance 28,770 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022.
Opus Genetics, Inc.
Report date February 28, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,750 |
Reported balance
After 2019-02-28 transaction · row 1
1 source rowRow 1 · 2019-02-28 · Exercise / conversion · Acquired 2,375 · Balance 4,750 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,750 |
Reported balance
After 2019-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-28 · Exercise / conversion · Disposed 2,375 · Balance 4,750 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February, beginning February 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F2: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February, beginning February 28, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2020 Filed Aug 3, 2020 21:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 341 | $76.39 | $26,048.31 |
DisclosureSEC source: 0001645113-20-000114 · wf-form4_159649157316820.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,016 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 07, 2020 Filed Aug 3, 2020 21:53 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000114 · wf-form4_159649157316820.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,357 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,595 | $64.78 | $168,104.10 |
DisclosureSEC source: 0001645113-20-000083 · wf-form4_158948727942417.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,616 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,611 | $63.73 | $102,665.81 |
DisclosureSEC source: 0001645113-20-000079 · wf-form4_158931495360958.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,211 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Share Units · Derivative | 4,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000079 · wf-form4_158931495360958.xml · derivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 Underlying: Ordinary Shares · 4,206 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 4,206 | $63.84 | $268,511.04 |
DisclosureSEC source: 0001645113-20-000079 · wf-form4_158931495360958.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 23:46 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 27,794 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001632237-20-000001 · primary_doc.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,794 Underlying: Ordinary Shares · 27,794 shares Expires 2030-03-02 F2 · derivative.exercise_date: Options to buy 27,794 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 23:46 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 14,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001632237-20-000001 · primary_doc.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,032 F1 · shares: Represents restricted share units that are scheduled to vest on March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 5,206 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001209191-19-044006 · doc4.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,206 Underlying: Ordinary Shares · 5,206 shares Expires 2029-07-30 F2 · derivative.exercise_date: Options to buy 5,206 ordinary shares will fully vest and become exercisable in equal installments on each of July 30, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 3,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044006 · doc4.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,617 F1 · shares: One-third of these restricted stock units are scheduled to vest on each of July 30, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:35 UTC | Opus Genetics, Inc. RNN · Entity 5892 | Exercise / conversionRestricted Stock Units · Derivative | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-19-004274 · form4.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February, beginning February 28, 2020. F2 · derivative.expiration_date: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February, beginning February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:35 UTC | Opus Genetics, Inc. RNN · Entity 5892 | Exercise / conversionCommon Stock | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-19-004274 · form4.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 26, 2019 00:52 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001140361-19-001633 · form4.xml · derivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on January 25, 2020, and, thereafter, 1/36th of the remaining option vests in equal installments on each monthly anniversary of such date until fully vested. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:12 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001140361-18-012871 · form4.xml · derivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on March 7, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:39 UTC | Opus Genetics, Inc. RNN · Entity 5892 | Exercise / conversionRestricted Stock Units · Derivative | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011667 · form4.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019. F2 · derivative.expiration_date: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:39 UTC | Opus Genetics, Inc. RNN · Entity 5892 | Exercise / conversionCommon Stock | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011667 · form4.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 45,443 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001140361-18-003889 · form4.xml · derivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,443 Underlying: Common Stock · 45,443 shares Expires 2028-01-26 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on January 26, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:48 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantRestricted Stock Units · Derivative | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002735 · form4.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:48 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001140361-17-002735 · form4.xml · derivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-01-20 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.